ST交昂(600530) - 2020 Q3 - 季度财报

Financial Performance - Net profit attributable to shareholders decreased by 41.34% year-on-year, totaling RMB 54,561,006.53 for the first nine months[8] - Operating income increased by 2.11% year-on-year, reaching RMB 251,914,780.47 for the first nine months[8] - Basic earnings per share decreased by 41.18% to RMB 0.070[8] - Total revenue for Q3 2020 was CNY 95,466,803.66, a decrease of 13.7% compared to CNY 110,610,787.34 in Q3 2019[32] - The company's net loss for Q3 2020 was CNY 3,123,306.41, compared to a loss of CNY 305,171.28 in Q3 2019[32] - The company's operating profit for Q3 2020 was ¥-10,130,194.16, compared to an operating profit of ¥9,208,348.79 in Q3 2019, marking a decline of 209.8%[36] - The total profit for Q3 2020 was ¥-9,565,442.27, down from ¥9,206,548.79 in Q3 2019, reflecting a decrease of 204.3%[36] - The total comprehensive income for Q3 2020 was ¥29,338,863.46, compared to ¥31,885,455.43 in Q3 2019, a decrease of approximately 7.9%[34] Asset and Liability Changes - Total assets decreased by 7.47% year-on-year, amounting to RMB 1,310,007,223.72 at the end of the reporting period[8] - Total assets decreased to ¥1,310,007,223.72 from ¥1,415,800,418.59, reflecting a decline in both current and non-current assets[27] - Total liabilities decreased to CNY 439,763,668.38 from CNY 623,951,371.70 year-over-year[31] - The total assets as of the end of Q3 2020 amounted to ¥1,415,800,418.59, with total liabilities at ¥623,647,520.87, resulting in total equity of ¥792,152,897.72[49] - The company’s retained earnings showed a deficit of -¥223,383,329.91, indicating challenges in profitability[49] Cash Flow and Financial Health - The net cash flow from operating activities decreased by 36.47% year-on-year, amounting to RMB 35,663,404.09[8] - Cash and cash equivalents decreased by 35.32% year-on-year, totaling RMB 117,611,101.44[14] - The net cash flow from operating activities for the first three quarters of 2020 was ¥35,663,404.09, a decrease of 36.5% compared to ¥56,133,052.50 in the same period of 2019[41] - Total cash inflow from operating activities was ¥261,496,412.21, down from ¥319,193,209.98 in the previous year, reflecting a decline of 18.1%[41] - The company incurred cash outflows of ¥225,833,008.12 from operating activities, down from ¥263,060,157.48 in the same period of 2019[41] - The total cash outflow from financing activities was ¥189,196,439.61, compared to ¥260,457,268.93 in the previous year, indicating a reduction of 27.3%[42] Expense Management - Operating costs rose to ¥128,340,449.63, reflecting a significant increase of 15.55% from ¥111,072,880.32 in the prior period, primarily due to increased costs in the pharmaceutical sector[17] - Sales expenses decreased by 23.41% to ¥40,546,554.10 from ¥52,937,954.69, attributed to better cost control measures[17] - Financial expenses surged by 110.69% to ¥4,868,739.56, up from ¥2,310,829.46, mainly due to increased borrowing interest[17] - R&D expenses decreased by 42.46% to ¥8,316,124.31 from ¥14,453,646.89, indicating a reduction in investment in research and development[17] - Research and development expenses for Q3 2020 were CNY 2,495,855.31, down from CNY 4,205,907.97 in Q3 2019[32] Shareholder Information - The number of shareholders reached 29,695 at the end of the reporting period[12] - The total equity attributable to shareholders increased to CNY 793,554,089.14 from CNY 752,585,076.34 year-over-year[30] - Basic and diluted earnings per share for the third quarter were both -¥0.012, compared to ¥0.015 in the same quarter of 2019[38]